Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, Texas, USA.
Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Obesity (Silver Spring). 2024 Sep;32(9):1613-1631. doi: 10.1002/oby.24067. Epub 2024 Jun 10.
The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well-being and promote optimal nutritional and medical outcomes.
最近批准和新出现的抗肥胖药物（AOM）的疗效提高和普遍良好的安全性特征，平均减重≥15%，代表了肥胖治疗的重大进展。本叙述性综述旨在为接受 AOM 治疗的患者的营养评估、管理和监测提供实用的循证建议。在治疗前，临床医生可以识别出先前存在的营养风险因素，并就蛋白质、膳食纤维、微量营养素和液体的推荐摄入量对患者进行咨询。在使用 AOM 治疗期间，持续监测可以促进早期识别和管理胃肠道症状或营养素或液体摄入不足。还应注意其他可能影响治疗反应和生活质量的因素，如身体活动以及社会和情感健康。在使用 AOM 治疗的情况下，临床医生可以在支持肥胖患者改善健康和幸福感以及促进最佳营养和医疗结果方面发挥积极作用。
